Cellyan Biotechnology Co., Ltd revenue by segment HKPD
Cellyan Biotechnology Co., Ltd splits its revenue into 3 lines in its filings. The largest line in fiscal 2025, which ended Mar 31, 2025 was Supply Chain Services at $12.5 million, 61% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2025
Mar 31, 2025
|
|---|---|
| Revenue |
20
|
| Supply Chain Services |
12
share 61.4%
|
| Procurement And Distribution |
8
share 37.0%
|
| Consignment Sales And Other Revenue |
0
share 1.6%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.
Company profile
- Industry
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (SIC 5122)
- Listed as
- HKPD (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- Cayman Islands
- Headquarters
- Kowloon
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 2007702
- Former names
- Hong Kong Pharma Digital Technology Holdings Ltd (until Dec 17, 2025)
Other Wholesale-Drugs, Proprietaries & Druggists' Sundries companies
- Mckesson Corp MCK
- Cencora, Inc. COR
- Cardinal Health Inc CAH
- Herbalife Ltd. HLF
- Nu Skin Enterprises, Inc. NUS
- EnerSyn Global Inc. ESYN
- Cosmos Health Inc. COSM
- DataMeds AI, Inc. MEDS
All 11 Wholesale-Drugs, Proprietaries & Druggists' Sundries companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.